FDA 483 - Bell-More Labs, Inc. - June 07, 2021

An FDA inspection of Bell-More Laboratories Inc. in Hampstead, MD, revealed significant deficiencies across its manufacturing and quality control operations. The firm failed to maintain adequate aseptic processing conditions, environmental monitoring, and cleaning validations. Furthermore, issues were identified with data integrity, equipment maintenance, process validations, and the overall effectiveness of the quality control unit, indicating systemic failures in ensuring drug product quality and sterility.